| Field | Specification |
|---|---|
| Mfr No | |
| Species |
MDA-MB-175-VII is a human breast cancer cell line originally derived from the pleural effusion of an adult female patient with infiltrating ductal mammary carcinoma. The cell line is part of a series established from metastatic breast tumors to provide viable, fibroblast-poor epithelial cultures. Specifically, MDA-MB-175 was isolated from six of eight thoracenteses performed on a patient who underwent mastectomy and exhibited recurrent malignant pleural effusions. The tumor cells were consistently viable and cultured successfully across samples, which provided a stable platform for in vitro studies of metastatic breast cancer biology.
MDA-MB-175-VII cells are morphologically epithelial and have a modal chromosome number of approximately 49, reflecting an aneuploid karyotype. These cells exhibit relatively slow growth in vitro but have gained scientific interest due to their unique molecular features, including the expression of neuregulin-1 (NRG1) fusion transcripts. In particular, the NRG1-DOC4 fusion observed in this line leads to constitutive activation of the HER3/HER4 receptor pathway, promoting autocrine signaling and cell proliferation. This molecular characteristic has positioned MDA-MB-175-VII as a rare but critical model for studying autocrine HER-family receptor signaling and its pharmacological targeting in breast cancer .
Further integration into large-scale datasets such as the Cancer Cell Line Encyclopedia (CCLE) has enabled deeper molecular profiling of MDA-MB-175-VII. These datasets include transcriptomic, mutational, and proteomic information that support the classification of the cell line within the luminal subtype of breast cancers, with modest sensitivity to agents targeting HER-family receptors and PI3K signaling pathways. As such, MDA-MB-175-VII serves as a valuable model for preclinical investigations of targeted therapies and the functional consequences of oncogenic gene fusions in breast cancer.
—
- Isoenzymes: AK-1, 1
- ES-D, 1
- G6PD, B
- GLO-I, 1-2
- PGM1, 2
- PGM3, 1-2
- Tumorigenic: Yes;
- Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells.
- Mutational profile: Mutation: Gene fusion, NRG1 + HGNC, TENM4, Name(s)=TENM4-NRG1, DOC4-NRG1, Note=In frame.
- Karyotype: model number = 84; range = 82 to 89
- cultureMedium: DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a)
- supplements: Supplement the medium with 10% FBS + Insulin (5 microgram/ml)
- dissociationReagent: Accutase
- doublingTime: 112 hours
- fluidRenewal: 2 to 3 times per week
- freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
10%
OFF
15%OFF
20%
OFF
$50
OFF
FREE
SAMPLE
